Bemnifosbuvir + Ruzasvir for Chronic Hepatitis C

"This clinical trial is running from four separate sites in Constanţa, Craiova, and Bucuresti as well as an additional 4 locations. It would be prudent for potential participants to select the clinic nearest to them so they can conserve energy on any necessary transportation."

"This clinical trial is accepting adult participants ranging from 18 to 85 years of age."

"Our team at Power has judged the safety of Bemnifosbuvir and Ruzasvir to be a 2, as this is only a Phase 2 trial with evidence backing its security but not yet its efficacy."

"Affirmative. According to the information on clinicaltrials.gov, this research project is actively enrolling patients and has been since its posting date of May 30th 2023; there have also been recent updates as recently as August 1st 2023. The study requires 280 participants from four different medical locations."

"Yes, the data posted on clinicaltrials.gov confirms this investigation is actively recruiting patients which began on May 30th 2023 and was recently refreshed on August 1st 2023. This trial requires 280 participants to be recruited from 4 separate sites."

"This clinical trial is seeking 280 candidates with hepatitis c, aged 18-85. To be eligible for inclusion in the study, participants must fulfil additional criteria such as providing written informed consent and agreeing to abstain from heterosexual intercourse or use effective contraception if female of childbearing potential. Additionally, suitable applicants should have never been exposed to approved/experimental direct-acting antivirals (DAAs) and present a documented medical history compatible with chronic HCV alongside an absence of cirrhosis (F0 - F3), or compensated cirrhosis (F4)."